Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology. The company offers MOVANTIK, an oral peripherally-acting mu-opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives. Its drug candidates in clinical development stage comprises BAX 855 that is in Phase III clinical trial for treating Hemophilia A; BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-181 that is in Phase III clinical trial for chronic pain; NKTR-171, which is in Phase I clinical trial to treat neuropathic pain; and NKTR-214 that is in research and preclinical trial stage to treat oncology, as well as MOVANTIK, which is research and preclinical stage for treating chronic pain without constipation. The company’s drug candidates in clinical development stage also include etirinotecan pegol, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as has completed Phase II clinical trial stage for platinum-resistant/refractory ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat gastrointestinal-related solid tumors, which has completed Phase I clinical trial. Nektar Therapeutics has collaboration with Baxter Healthcare; Bayer Healthcare LLC; and AstraZeneca AB. In addition, it has license, manufacturing, and supply agreements with Amgen Inc.; Allergan, Inc.; Halozyme Therapeutics, Inc.; Merck & Co., Inc.; Ophthotech Corporation; Pfizer, Inc.; F. Hoffmann-La Roche Ltd (Roche); and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.